首頁 > 市場調查報告書 > 製藥

神經疾病

脊髓性肌肉萎縮症 (SMA) 治療市場規模、佔有率和成長分析：按治療方法、SMA 類型、給藥途徑、最終用戶和地區分類—2026-2033 年產業預測

市場調查報告書

商品編碼

2064697

脊髓性肌肉萎縮症 (SMA) 治療市場規模、佔有率和成長分析：按治療方法、SMA 類型、給藥途徑、最終用戶和地區分類—2026-2033 年產業預測

Spinal Muscular Atrophy Treatment Market Size, Share, and Growth Analysis, By Treatment Type (Gene Therapy (Zolgensma), Antisense Oligonucleotides (Spinraza)), By SMA Type, By Administration, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年06月04日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球脊髓性肌肉萎縮症 (SMU) 治療市場價值為 38.2 億美元，預計到 2025 年將成長至 42.3 億美元，到 2033 年將成長至 95.2 億美元，在預測期（2026-2033 年）內複合成長率為 10.62%。

脊髓性肌肉萎縮症 (SMR) 的全球治療市場正受到標靶疾病修正治療的顯著影響。這使得這種嚴重神經肌肉疾病的治療重點從症狀管理轉向基因介入。由領先製造商開發的創新治療方法正在顯著延長患者的平均壽命，減少長期照護的需求，並創造巨大的商業機會。基因療法的進步和精準醫療的興起（得益於新生兒篩檢計畫的改進）使得更早發現和評估治療合格成為可能，從而改善了患者的預後。此外，人工智慧技術透過增強標靶識別、最佳化臨床試驗設計和簡化生產流程，正在加速藥物研發。這些進步正在促進與人工智慧公司的合作，加速有效治療方法的研發進程，推動新興市場的成長，從而重塑 SMR 的治療方式。

全球脊髓性肌肉萎縮症治療市場促進因素

脊髓性肌肉萎縮症 (SMA) 基因治療的進展顯著拓寬了治療選擇，提供了更精準、更持久的解決方案，在改善患者功能的同時，也減輕了持續的症狀負擔。載體設計和遞送策略的創新，以及對疾病機制更深入的理解，為更廣泛的治療應用鋪平了道路。這項進展刺激了臨床實務中持續的投資和探索，促使醫療專業人員和製藥公司等相關人員優先考慮研發，並加速新治療方法的開發。因此，這種活力正在促進永續的合作，旨在加速創新治療方法的出現，並為患者帶來持久的益處。

全球脊髓性肌肉萎縮症治療市場面臨的限制因素

全球脊髓性肌肉萎縮症 (SMU) 治療市場面臨許多挑戰，包括高昂的治療費用，導致難以提供價格合理的治療方案，並限制了患者的就醫途徑。高昂的價格引起了支付方的密切關注，延緩了有效臨床療法的推廣。此外，沉重的經濟負擔也使得醫療系統在廣泛採用新治療方法猶豫不決，導致保險覆蓋範圍有限，且需要預先批准。這種情況可能會阻礙醫療服務提供者開立這些治療方法，也可能影響製造商大規模商業化的意願。最終，確保不同醫療環境下的治療可近性需要價格調整、價值驗證以及永續的、長期可負擔的解決方案，而所有這些因素都在阻礙市場成長。

脊髓性肌肉萎縮症治療的全球市場趨勢

全球脊髓性肌肉萎縮症 (SMU) 治療市場正經歷著向精準基因治療的顯著轉變，這主要得益於對疾病機制的深入理解以及載體技術的創新。這項進步為個人化基因治療方法鋪平了道路，這些療法有望提供更長期的療效並最終治癒疾病。業內相關人員日益關注個人化給藥策略，與監管機構合作創新臨床實驗設計，並建立策略夥伴關係，以加速從研究到臨床應用的轉化。這些進展不僅為研發者帶來了競爭優勢，也鼓勵了對專業化生產的投資，並透過重塑支付方的考量和臨床路徑，確保患者獲得持續的積極療效。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Biogen（Spinraza）
Novartis（Zolgensma）
Roche（Evrysdi）
AveXis（Novartis）
Scholar Rock
Cytokinetics
Ionis Pharmaceuticals
PTC Therapeutics
Sarepta Therapeutics
Wave Life Sciences
Astellas Gene Therapies
Brainstorm Cell Therapeutics
Passage Bio
Solid Biosciences
Design Therapeutics

結論與建議

簡介目錄

Product Code: SQMIG35H2541

Global Spinal Muscular Atrophy Treatment Market size was valued at USD 3.82 Billion in 2024 and is poised to grow from USD 4.23 Billion in 2025 to USD 9.52 Billion by 2033, growing at a CAGR of 10.62% during the forecast period (2026-2033).

The global spinal muscular atrophy treatment market is significantly influenced by the emergence of targeted disease-modifying therapies, which have shifted the focus from symptom management to genetic intervention for this debilitating neuromuscular disorder. Innovative therapies, such as those developed by leading manufacturers, have drastically improved life expectancy and reduced long-term care requirements, creating substantial commercial opportunities. The trend toward precision medicine, bolstered by advancements in genetic therapies and enhanced newborn screening programs, has allowed for early detection and treatment eligibility, improving patient outcomes. Additionally, AI technologies are accelerating drug development by enhancing target identification, optimizing clinical trial designs, and streamlining manufacturing processes. These developments foster collaboration with AI firms, facilitating faster progress toward effective therapies and enabling growth in emerging markets, thereby reshaping the treatment landscape for spinal muscular atrophy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Spinal Muscular Atrophy Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Spinal Muscular Atrophy Treatment Market Segments Analysis

Global spinal muscular atrophy treatment market is segmented by treatment type, sma type, administration, end-user and region. Based on treatment type, the market is segmented into Gene Therapy (Zolgensma), Antisense Oligonucleotides (Spinraza), Small Molecule (Evrysdi) and Supportive Care. Based on sma type, the market is segmented into SMA Type I, SMA Type II and SMA Type III. Based on administration, the market is segmented into Intrathecal, Oral and Intravenous. Based on end-user, the market is segmented into Hospitals, Specialty Neurology Centers and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Spinal Muscular Atrophy Treatment Market

The advancements in gene therapy for spinal muscular atrophy have significantly enhanced treatment options, offering more precise and long-lasting solutions that improve patient functionality while easing the ongoing burden of symptoms. Innovations in vector design, delivery strategies, and the deepening understanding of disease mechanisms have opened avenues for a wider range of therapeutic applications. This progress inspires ongoing investment and exploration within the clinical landscape, driving stakeholders such as healthcare professionals and manufacturers to prioritize research and expedite the development of new therapies. Consequently, this dynamic fosters the emergence of innovative treatment options and cultivates sustainable collaborations aimed at ensuring lasting benefits for patients.

Restraints in the Global Spinal Muscular Atrophy Treatment Market

The global spinal muscular atrophy treatment market faces significant barriers due to the high costs associated with therapies, which create affordability issues and restrict patient access. These elevated prices lead to increased scrutiny from payers and slow the adoption of beneficial clinical treatments. Additionally, the financial burden can deter healthcare systems from widely implementing new treatments, resulting in restrictive coverage policies and the need for prior authorization. This situation may discourage healthcare providers from prescribing such therapies and impact manufacturers' willingness to pursue broad commercialization. Ultimately, the market's growth is hindered by the necessity for price adjustments, evidence of value, and sustainable long-term affordability solutions to ensure access in various healthcare environments.

Market Trends of the Global Spinal Muscular Atrophy Treatment Market

The Global Spinal Muscular Atrophy Treatment market is witnessing a significant trend towards precision gene therapy, driven by an enhanced understanding of the disease mechanisms and innovations in vector technology. This advancement is paving the way for personalized, gene-based therapies that offer longer-lasting efficacy and potential cures. Industry stakeholders are increasingly focusing on tailored dosing strategies, engaging with regulatory bodies to innovate trial designs, and forming strategic partnerships to expedite the transition of research to clinical applications. Such dynamics not only cultivate competitive advantages for developers but also encourage investment in specialized manufacturing, reshaping both payer considerations and clinical pathways to ensure sustained positive patient outcomes.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Spinal Muscular Atrophy Treatment Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Gene Therapy (Zolgensma)
Antisense Oligonucleotides (Spinraza)
Small Molecule (Evrysdi)
Supportive Care

Global Spinal Muscular Atrophy Treatment Market Size by SMA Type & CAGR (2026-2033)

Market Overview
SMA Type I
SMA Type II
SMA Type III

Global Spinal Muscular Atrophy Treatment Market Size by Administration & CAGR (2026-2033)

Market Overview
Intrathecal
Oral
Intravenous

Global Spinal Muscular Atrophy Treatment Market Size by End-User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Neurology Centers
Home Care

Global Spinal Muscular Atrophy Treatment Market Size & CAGR (2026-2033)

North America (Treatment Type, SMA Type, Administration, End-User)
- US
- Canada
Europe (Treatment Type, SMA Type, Administration, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, SMA Type, Administration, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, SMA Type, Administration, End-User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, SMA Type, Administration, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen (Spinraza)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis (Zolgensma)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Evrysdi)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AveXis (Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Scholar Rock
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytokinetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ionis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PTC Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sarepta Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wave Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Gene Therapies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Brainstorm Cell Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Passage Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Solid Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Design Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments